article
Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
List view / Grid view
Monoclonal Antibody
article
Women in STEM with Dr Jane Osbourn
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
news
Experimental mAbs show promise against Epstein-Barr virus
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
news
New findings show a monoclonal antibody could target heroin addiction
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
news
Newly discovered SARS-CoV-2-like virus could infect humans and resist vaccines
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
article
In search of COVID-19 antibodies
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
news
A new study has highlighted how an antibody strengthens bonds between cells
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
news
Scientists discover an antibody that potentially acts as a therapy against SARS-CoV-2
The scientists found that the neutralising monoclonal antibody protected against SARS-CoV-2 infections in animal experiments.
podcasts
Episode 6 – mAbs and SARS-CoV-2 with Dr Carter Mitchell & Dr Sharath Madasu, Kemp Proteins
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
article
Ensuring the safety and efficacy of biologics products
In this article, Dr Shishir Chundawat and Aron Gyorgypal from Rutgers University, US, explain how they developed a new process analytical technology (PAT) system for the automated monitoring of antibody N-glycosylation.
news
Sino Biological launches panel of research reagents for SARS-CoV-2 Omicron variant (B.1.1.529)
Sino Biological, Inc. has just launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world due to the high number of mutations it carries, particularly the 30-plus mutations on the Spike protein.
article
Drug Target Review Upstream Bioprocessing ebook 2021
In this ebook, find an article on 3D tissue cultures from biopsy samples to evaluate the preservation of tissue-typical protein expressions as well as a piece on a new process analytical technology (PAT) system to assess N-glycosylation during upstream cell culture bioprocessing.